跳至主要内容
临床试验/NCT01238328
NCT01238328Unknown2 期

Hematopoietic Stem Cell Transplantation for Mucopolysaccharidosis

Tehran University of Medical Sciences1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2009年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
入组人数
10
试验地点
1
主要终点
Overall Survival and Progressive Free Survival in patient with Mucopolysaccharidosis who receive allogeneic Hematopoietic stem cell transplantation (HSCT)

研究概览

简要总结

The purpose of this study is to evaluate the efficacy and side effects of donor hematopoietic cells using chemotherapy regimen without total-body irradiation in children undergoing a hematopoietic stem cell transplant for Mucopolysaccharidosis. The blood stem cells will be derived from either related donor or unrelated umbilical cord blood or haploidentical donor.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
— 至 8 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of Mucopolysaccharidosis type 1, 6 and 7 confirm by leukocyte enzyme assay
  • Age up to 8 year old
  • Have suitable donor

排除标准

  • Creatinine clearance ≤ 40ml/min/1.73m^2
  • Bilirubin ≥ 3mg/dL
  • SGPT ≥ 500 U/L
  • Current severe infection
  • Evidence of CNS involvement
  • Morbidity such as blindness or deafness

研究组 & 干预措施

Transplantation

Experimental

干预措施: Conditioning regimen (Drug)

Transplantation

Experimental

干预措施: Graft-versus-host disease (GVHD) prophylaxis (Drug)

Transplantation

Experimental

干预措施: Stem Cell Transplantation (Procedure)

结局指标

主要结局

Overall Survival and Progressive Free Survival in patient with Mucopolysaccharidosis who receive allogeneic Hematopoietic stem cell transplantation (HSCT)

时间窗: 1 year

次要结局

  • One year overall survival after allogeneic hematopoietic stem cell transplantation (HSCT)(1 year)
  • One year Progressive Free Survival after allogeneic hematopoietic stem cell transplantation (HSCT)(1 year)
  • Transplantation Related Mortality (TRM) after allogeneic hematopoietic stem cell transplantation (HSCT)(1 year)
  • Acute and chronic Graft-versus-host disease (GVHD) rate after allogeneic hematopoietic stem cell transplantation (HSCT)(1 year)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验